New blood test could spot sepsis faster, saving lives and antibiotics

NCT ID NCT07203833

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at whether a protein called vasorin (Vasn) in the blood can help doctors quickly tell the difference between septic shock (caused by infection) and other types of shock (like after heart surgery). Currently, the best test for this is not always accurate. The researchers will measure vasorin levels in 144 intensive care patients and see if it can better guide treatment decisions, such as whether antibiotics are needed. They will also check if vasorin levels can predict which patients are at higher risk of dying within 28 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 144 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults over 18 years. * Patients admitted for less than 24 hours in intensive care unit of the CHU Amiens Picardie. * Group 1: patients with septic shock defined by sepsis with 2 mmol/l Lactates, requiring vasopressors to maintain mean blood pressure at 65 mmHg (despite adequate vascular filling) in the presence of fever (T°\>38.3) with a documented or suspected infection * Group 2: patients with a shock defined by arterial hypotension requiring the use of vasopressors with 2 mmol/l Lactates but without suspected infection and apyrexie (T°\<38°). For example: vasoplegia post cardiac surgery with CBP or cardiogenic shock or hemorrhagic shock Exclusion Criteria: * Pregnant women * Group 1 : No evidence of suspected or documented infection * Group 2 : Presence of fever and/or suspected infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biomarker are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Infections infectious disease Shock toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biomarker Infection Septic shock Shock Vasorin

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

New blood test could spot sepsis faster, saving lives and antibiotics

What the study statuses mean